Unlock instant, AI-driven research and patent intelligence for your innovation.

Anti-CCL25 and anti-CCR9 antibodies for the prevention and treatment of cancer and cancer cell migration

An antibody and cancer technology, applied in the direction of antibodies, antibody medical components, anti-cytokine/lymphokine/interferon immunoglobulin, etc., can solve the problems of adverse side effects, side effects, and the development of targeted therapy methods.

Inactive Publication Date: 2016-12-07
JYANT TECH
View PDF37 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

A number of complex factors (capable of mutating malignant cells, evading immune protection and promoting angiogenesis, which provides nutrients for rapidly growing cells) complicate the development of targeted therapeutic modalities
Current therapies have multiple adverse side effects
For example, chemotherapy causes many painful and sometimes fatal side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-CCL25 and anti-CCR9 antibodies for the prevention and treatment of cancer and cancer cell migration
  • Anti-CCL25 and anti-CCR9 antibodies for the prevention and treatment of cancer and cancer cell migration
  • Anti-CCL25 and anti-CCR9 antibodies for the prevention and treatment of cancer and cancer cell migration

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0169] Example 1: In Vitro Analysis of CCL25 and CCR9 Expression and Activity in Various Cancers

[0170] as in figure 1 As shown in , breast cancer tissues express CCL25. Breast cancer tissues were stained with isotype control or anti-CCL25 antibody. Magenta shows CCL25 staining. Digital images were captured by an Aperio ScanScope CS system with a 40X objective lens. The classic example of breast cancer shows the immune strength of CCL25.

[0171] figure 2 demonstrated that CCL25 inhibits cisplatin-induced reduction in growth of breast cancer cell lines. MDA-MB-231 cells were incubated with 0 or 100 ng / ml CCL25 plus isotype control or anti-CCR9 Ab for 24 hours with increasing cisplatin concentration. Cell proliferation was assayed by BrdU incorporation, and the assay was repeated 3 times and performed in triplicate. Asterisks indicate statistically significant differences (p<0.01) between CCL25-treated and untreated BrCa cells.

[0172] Figure 3A-B shows that CCL...

Embodiment 2

[0195] Example 2: Detection of Chemokine Expression Levels Using Real-Time PCR Analysis

[0196] Primer design

[0197] CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, CXCL16, CXCR1, CXCR2, CXCR3, CXCR4, CXCR5, CXCR5aX, CXCR5b, CCR7 CCL1, CCL2, CCL3, CCL4, CCL5, CCL6, CCL7, CCL8, CCL9, CCL10, CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL24, CCL25, CCL25- 1. The messenger RNA sequence of CCL25-2, CCL27, CCL28, CCR1, CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10, CCR11, XCL1, XCL2, XCR1, CX3CR1 or CX3CL1 was obtained from NIH-NCBI Genebank database. Primers were designed using the BeaconJ 2.0 computer program. Thermodynamic analysis of primers was performed using computer programs: Primer PremierJ and MITPrimer 3. The resulting primer sets were compared against the entire human genome to determine specificity.

[0198] real-time PCR analysis

[0199] Cancer ce...

Embodiment 3

[0201] Example 3: Anti-chemokine and anti-chemokine receptor antibodies inhibit tumor cell growth in vitro and in vivo

[0202] antiserum products

[0203] From CXCR1, CXCR2, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, CXCL8, CXCL12, CXCR5a, CXCR5b, CXCL13, CXCR6, CXCL16, CCL16, CCL25, CCL25-1, CCL25-2, CCR9, CX3CR1 and CX3CL1 ( 15 amino acid peptides of SEQ ID NOS:1-SEQ ID NO:21) were synthesized (Sigma Genosys, The Woodlands, TX) and combined with chicken egg lysozyme (Pierce, Rockford, IL) to generate antiserum preparations or monoclonal Antibody to the antigen for subsequent immunizations. Endotoxin levels of chemokine peptide conjugates were quantified by the chromogenic limulus amoeba cell lysate assay (Cape Cod, Inc., Falmouth, MS) and shown as <5 EU / mg. For the first immunization, 100 μg of antigen was used as immunogen in a final volume of 1.0 ml together with complete Freund's adjuvant Ribi Adjuvant System (RAS). The mixture was administered subcutaneously in 100 ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The discourse discloses a method for the prevention or suppression of the growth or migration of cancer cells in a subject. The method includes a step of applying effective dose of CCL25 and / or CCR9 antibodies to the subject. The other method includes a step of applying effective dose of expression vector for expressing CCL25 and / or CCR9 antibodies to the subject.

Description

[0001] This application is a divisional application of the invention patent application "anti-CCL25 antibody and anti-CCR9 antibody for the prevention and treatment of cancer and cancer cell migration". The national application number of the parent case is "2011800671265", and the PCT international filing date is December 2011 On March 13, the PCT international application number is PCT / US2011 / 064667. [0002] This application claims the benefit of U.S. Patent Application No. 13 / 248,904, filed September 29, 2011, U.S. Patent Application No. 13 / 233,769, filed September 15, 2011, and U.S. Patent Application No. Priority of Patent Application No. 12 / 967,273. All of the aforementioned applications are incorporated herein by reference in their entirety. technical field [0003] This application mainly relates to the field of antibodies. In particular, the application relates to the use of anti-chemokine and / or anti-chemokine receptor antibodies for inhibiting or preventing growth...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/395A61P35/00A61P35/02
CPCC07K16/24C07K16/2866A61K2039/543A61K2039/542A61K2039/507A61K2039/505A61K2039/544A61K2039/545C07K2317/73A61K2300/00A61P35/00A61P35/02A61P35/04A61P37/04A61P43/00
Inventor 詹姆斯·W·利拉德沙伊莱什·辛格拉杰什·辛格
Owner JYANT TECH
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com